非对称二甲基精氨酸参与CKD贫血中对促红细胞生成素反应受损
在54例晚期CKD患者中,红细胞ADMA水平而非血浆ADMA独立关联低血红蛋白;红细胞ADMA与ESA抵抗指数或EPO需求指数相关。5/6肾切除小鼠中红细胞和血浆ADMA升高,DDAH-1转基因小鼠代谢ADMA后贫血改善,提示红细胞ADMA通过抑制EPO受体表达损害EPO反应。
要点
- 红细胞ADMA独立关联晚期CKD患者低血红蛋白。
- 红细胞ADMA与ESA抵抗指数或EPO需求指数相关。
- DDAH-1转基因小鼠代谢ADMA后贫血改善。
核心结论
- 红细胞ADMA蓄积通过抑制EPO受体表达参与晚期CKD患者和小鼠对EPO反应受损。
研究设计与样本
- 54例晚期CKD患者临床观察。
- 5/6肾切除野生型小鼠与DDAH-1转基因小鼠对照实验。
主要发现
- 晚期CKD患者红细胞和血浆ADMA水平均高于健康志愿者。
- 红细胞ADMA独立关联低血红蛋白,血浆ADMA无此关联。
- 接受ESA者红细胞ADMA与ESA抵抗指数相关,未接受ESA者与EPO需求指数相关。
- 5/6肾切除野生型小鼠血红蛋白、血细胞比容和平均红细胞体积降低,红细胞和血浆ADMA及血浆EPO升高。
- DDAH-1转基因小鼠除EPO外上述指标均显著改善,且脾EPO受体和红铁酮基因表达未降低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Erythropoietin-resistant anemia is associated with adverse cardiovascular events in patients with ESRD, but the underlying mechanism remains unclear. Here, we evaluated the role of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA). In 54 patients with advanced CKD, erythrocyte but not plasma ADMA levels independently associated with low hemoglobin values, although levels of both types of ADMA were elevated compared with those in healthy volunteers. Furthermore, erythrocyte ADMA level associated with the erythropoietin resistance index in patients receiving a weekly injected dose of erythropoiesis-stimulating agents standardized for hemoglobin levels and body weight, whereas it correlated with the erythropoietin demand index (plasma erythropoietin units divided by the hemoglobin value) in patients not receiving erythropoiesis-stimulating agents. Compared with sham-operated controls, wild-type mice with 5/6 subtotal nephrectomy (Nx), a remnant kidney model with advanced CKD, had decreased hemoglobin, hematocrit, and mean corpuscular volume values but increased erythrocyte and plasma ADMA and plasma erythropoietin levels. In comparison, dimethylarginine dimethlaminohydrolase-1 transgenic (DDAH-1 Tg) mice, which efficiently metabolized ADMA, had significant improvements in all of the values except those for erythropoietin after 5/6 Nx. Additionally, wild-type Nx mice, but not DDAH-1 Tg Nx mice, had reduced splenic gene expression of erythropoietin receptor and erythroferrone, which regulates iron metabolism in response to erythropoietin. This study suggests that erythrocyte ADMA accumulation contributes to impaired response to erythropoietin in predialysis patients and advanced CKD mice via suppression of erythropoietin receptor expression.
引用
- Yokoro M, Nakayama Y, Yamagishi SI, et al. Asymmetric Dimethylarginine Contributes to the Impaired Response to Erythropoietin in CKD-Anemia. J Am Soc Nephrol. 2017. PMID: 28600471. doi:10.1681/ASN.2016111184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。